9th Joint ECTRIMS-ACTRIMS meeting – 11-13 October 2023
The following summarizes some of the highlights from Day 2 of ECTRIMS-ACTRIMS 2023.
Neurology
ECTRIMS-ACTRIMS 2023 HIGHLIGHTS – WEDNESDAY, OCTOBER 11 EDITION
October 11, 20239th Joint ECTRIMS-ACTRIMS meeting – 11-13 October 2023
The following summarizes some of the highlights from Day 1 of ECTRIMS-ACTRIMS 2023.
EYE TRACKING AS A BIOMARKER OF MS SEVERITY (NEUROSOUND PODCAST)
October 3, 2023Click here to listen to the podcast
A McGill University study has examined the potential usefulness of tracking eye movements as a biomarker of physical and cognitive dysfunction in patients with multiple sclerosis (de Villers-Sidani et al. Front Neurol 2023;14:1243594). Read More
Ofatumumab – update on long-term efficacy, safety
September 25, 2023SPECIAL REPORT
Long-term treatment with ofatumumab, a fully human anti-CD20 monoclonal antibody, is associated with a favourable safety profile and sustained efficacy, according to a newly-published analysis of the ALITHIOS long-term extension (Hauser et al. Mult Scler 2023; epublished September 11, 2023). The study is the most recent to support the earlier use of high-efficacy therapy in patients with multiple sclerosis. Read More
K-index a predictor of T2 lesions in CIS, RIS
September 14, 2023A new study has reported that the kappa free light chain index (K-index) can predict the occurrence of new T2 lesions in subjects with clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) (Levraut et al. Neurol Neuroimmunol Neuroinflamm 2023;10:e200156). The K-index was also useful to predict clinical events in CIS. Read More